Patients With PH1 Treated With Lumasiran in France

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Patients With PH1 Treated With Lumasiran in France trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT06225882

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by mutation in the AGXT gene encoding the hepatic peroxisomal enzyme AGT. Reduced AGT activi…

France100 participantsStarted 2023-01-01

Treatment: Oxaluria evolution.

Patients With PH1 Treated With Lumasiran in France

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

All recent trials (1 shown)